Authors
Latest:
Web-Based Tool for Symptom Reporting Leads to Longer Survival in Advanced Cancer PatientsPatients receiving treatment for metastatic cancer who used a web-based tool to report their symptoms either while at home or during clinic visits lived on average 5 months longer than their counterparts who had standard symptom monitoring.
Latest:
Improving Surveillance for Hepatocellular CarcinomaControversy over optimal surveillance methods for hepatocellular carcinoma (HCC) continues to drive ongoing investigation into improved biomarkers and imaging techniques.
Latest:
Bridging the Gap Between Disparities in Lung CancerLaurence J. Heifetz, MD, FACP, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses a novel approach to managing disparities in lung cancer care.
Latest:
Clinical Trials for Patients With Brain MetastasesLaurie E. Gaspar, FASTRO, FACR, MD, MBA, professor and chair of the Department of Radiation Oncology, University of Colorado Denver, discusses the importance of enrolling patients with brain metastases on clinical trials.
Latest:
Reducing Neurotoxicity in Lung CancerLaurie Gaspar, MD, discusses reducing neurotoxicity in small cell lung cancer patients.
Latest:
The Future of Precision Medicine and Genetic Testing in the CommunityLawrence D. Wagman, MD, FACS, executive medical director of St. Joseph’s Hospital, discusses the future of precision medicine and genetic testing in the community.<br />
Latest:
Inducing an Immune Response With a Patient’s TumorLawrence Fong, MD, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 (IL-12) in patients with advanced melanoma.
Latest:
Improving the Cure Rate and the Burden of Cure in Prostate CancerLawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Latest:
Which Frontline EGFR TKI Should be Used in NSCLC?Lecia V. Sequist, MD, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.
Latest:
Understanding EGFR Resistance in Patients With MET-Amplified NSCLCLecia V. Sequist, MD, MPH, director, says that oncologists have developed a better understanding of what causes resistance to EGFR inhibitors in patients with non–small cell lung cancer through preclinical studies and biopsies. <em>MET</em> amplification was found to be one of the major causes of resistance to newer generation EGFR-targeted drugs.
Latest:
Key Questions for Improving Outcomes With Pembrolizumab in PD-L1+ TNBCLee Schwartzberg, MD, discusses important questions that have been raised due to the positive results of pembrolizumab immunotherapy for patients with triple-negative breast cancer.
Latest:
First-Line Carboplatin and Pemetrexed With Pembrolizumab for NSCLCLeena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses first-line carboplatin and pemetrexed with or without pembrolizumab for advanced nonsquamous non–small cell lung cancer.
Latest:
IMpassion130 Data Demonstrate Clinical Benefit for Immunotherapy in Metastatic TNBCLeisha A. Emens, MD, PhD, professor of medicine at the UPMC Cancer Center, discusses how the data from the IMpassion130 trial have demonstrated benefit for immunotherapy in metastatic triple-negative breast cancer.
Latest:
Atezolizumab Added to T-DM1 Improves OS and PFS in HER2+ Breast CancerPositive overall survival data from the phase II KATE-2 study were presented at the 2019 ESMO Annual Meeting. Leisha Emens, MD, shares the results.
Latest:
Considering Genetic Testing in Patients With Prostate CancerLeonard G. Gomella, MD, discusses the factors that determine which patients with prostate cancer should undergo genetic testing.
Latest:
Advances in Cancer Biology Benefit Broad GU TreatmentsThe treatment landscape of genitourinary malignancies has seen tremendous growth in the last decade with advancements in prostate, bladder, and urothelial cancers.
Latest:
Future Outlook of the Ovarian Cancer Treatment LandscapeLeslie Randall, MD, MAS, offers closing thoughts on the future trajectory of ovarian cancer treatment.
Latest:
Significant Disparities in Access to Novel Agents For Patients With MelanomaLidija Kandolf Sekulovic, MD, PhD, associate professor of Dermatology, Military Medical Academy in Belgrade, Serbia, discusses a recently published survey during an interview at the 2016 ESMO Congress. The survey found that several thousand patients with metastatic melanoma in Europe do not have access to new, life-saving agents in this field.
Latest:
Body Composition and Targeted Therapies in Thyroid CancerLily Kwatampora, MD, discusses the relationship between body composition and targeted therapies in patients with thyroid cancer.
Latest:
Integration of Telehealth Raises New Challenges in Cancer CentersLinda Bosserman, MD, discusses the emerging role of telehealth and the challenges with implementing this type of care into cancer centers in the United States.
Latest:
Determining Resistance to a Taxane or Anthracyclines in Breast CancerLinda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she determines if a patient is resistant to a taxane or anthracyclines.
Latest:
Potential for Glembatumumab Vedotin in TNBCLinda T. Vahdat, MD, PhD, Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the ongoing METRIC trial and the potential for glembatumumab vedotin as a treatment for patients with triple-negative breast cancer (TNBC).
Latest:
Current Progress and Future With Glembatumumab Vedotin in TNBCLinda T. Vahdat, MD, PhD, Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the current progress being made with glembatumumab vedotin in triple-negative breast cancer (TNBC) and what the future holds for this agent.
Latest:
Dr. Linda Vahdat on Glembatumumab Vedotin as a Treatment in Triple Negative Breast CancerLinda Vahdat, MD, discusses the antibody drug conjugate glembatumumab vedotin being used in the treatment of women with triple negative breast cancer who have a high expression of gpNMB.
